Manandhar NR, Kayashta GK, Acharya PK. Dasatinib tyrosine kinase inhibitor as second and third line therapy in chronic myeloid leukemia: outcome of a Nepalese study. J Patan Acad Health Sci [Internet]. 2018 Jun. 29 [cited 2024 Apr. 26];5(1):47-56. Available from: https://www.nepjol.info/index.php/JPAHS/article/view/24042